Free Trial
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$298.39 +4.72 (+1.61%)
As of 03:57 PM Eastern

About Bio-Rad Laboratories Stock (NYSE:BIO)

Key Stats

Today's Range
$292.81
$300.85
50-Day Range
$235.92
$302.99
52-Week Range
$211.43
$387.99
Volume
199,920 shs
Average Volume
294,642 shs
Market Capitalization
$8.07 billion
P/E Ratio
25.44
Dividend Yield
N/A
Price Target
$333.50
Consensus Rating
Moderate Buy

Company Overview

Bio-Rad Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

BIO MarketRank™: 

Bio-Rad Laboratories scored higher than 89% of companies evaluated by MarketBeat, and ranked 115th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Rad Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Rad Laboratories has only been the subject of 3 research reports in the past 90 days.

  • Read more about Bio-Rad Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Rad Laboratories are expected to grow by 15.17% in the coming year, from $10.81 to $12.45 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Rad Laboratories is 25.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.48.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Rad Laboratories is 25.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 79.66.

  • Price to Book Value per Share Ratio

    Bio-Rad Laboratories has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bio-Rad Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    5.01% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently increased by 2.55%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Bio-Rad Laboratories does not currently pay a dividend.

  • Dividend Growth

    Bio-Rad Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.01% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently increased by 2.55%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Bio-Rad Laboratories has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Bio-Rad Laboratories this week, compared to 7 articles on an average week.
  • Search Interest

    Only 3 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Bio-Rad Laboratories to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.06% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Rad Laboratories' insider trading history.
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO Stock News Headlines

Bio-Rad Hosts Webinar on Digital PCR Advancements
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Bio-Rad Reports Second-Quarter 2025 Financial Results
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $328.51 at the beginning of the year. Since then, BIO shares have decreased by 9.2% and is now trading at $298.39.

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its quarterly earnings data on Thursday, July, 31st. The medical research company reported $2.61 earnings per share for the quarter, topping analysts' consensus estimates of $1.93 by $0.68. The business's quarterly revenue was up 2.1% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of Bio-Rad Laboratories: Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and others.

Top institutional investors of Bio-Rad Laboratories include First Eagle Investment Management LLC (9.25%), Ariel Investments LLC (3.02%), State Street Corp (2.16%) and Bank of America Corp DE (1.67%). Insiders that own company stock include Andrew J Last, Michael Crowley, Timothy S Ernst, Dara Wright, James Barry and Ajit Ramalingam.
View institutional ownership trends
.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
7/31/2025
Today
8/29/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:BIO
CIK
12208
Employees
7,700
Year Founded
1952

Price Target and Rating

High Price Target
$409.00
Low Price Target
$265.00
Potential Upside/Downside
+11.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$11.73
Trailing P/E Ratio
25.44
Forward P/E Ratio
27.60
P/E Growth
N/A
Net Income
-$1.84 billion
Net Margins
12.50%
Pretax Margin
17.62%
Return on Equity
4.01%
Return on Assets
2.82%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
5.12
Quick Ratio
3.67

Sales & Book Value

Annual Sales
$2.57 billion
Price / Sales
3.15
Cash Flow
$10.56 per share
Price / Cash Flow
28.26
Book Value
$263.42 per share
Price / Book
1.13

Miscellaneous

Outstanding Shares
27,060,000
Free Float
22,445,000
Market Cap
$8.07 billion
Optionable
Optionable
Beta
0.90

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:BIO) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners